Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity.
Fungal diseases have been emerging as an important public health problem worldwide with the increase in host predisposition factors due to immunological dysregulations, immunosuppressive and/or anticancer therapy. Antifungal therapy for systemic mycosis is limited, most of times expensive and causes important toxic effects. Nanotechnology has become an interesting strategy to improve efficacy of traditional antifungal drugs, which allows lower toxicity, better biodistribution, and drug targeting, with promising resultsin vitroandin vivo. In this review, we provide a discussion about conventional antifungal and nanoantifungal therapies for systemic mycosis.
Laboratory of Pathogenic Dimorphic Fungi, Institute of Biomedical Sciences, University of São Paulo São Paulo, Brazil.
Ana C O
AC
Souza
Laboratory of Nano and Biotechnology, Institute of Tropical Pathology and Public Health, Federal University of Goiás Goiânia, Brazil.
Andre C
AC
Amaral
antifungal therapy; drug delivery systems; fungal infection; mycosis; nanobiotechnology